PRESS RELEASE FROM THE MINISTRY OF HEALTH AND HUMAN SERVICES Cockburn Town, Turks and Caicos Islands, 2nd May 2025: In ...

Of the total ER visits, nearly 70% involved GI issues, 15% of which led to hospitalization, according to a new study.

Novo Nordisk shares rose by more than 5% after the Danish weight-loss drug maker said the Food and Drug Administration accepted a new drug application for a pill form of its popular Wegovy injection.

Health Canada begins a priority review of semaglutide 2.4 mg, a weekly treatment by Novo Nordisk for MASH, a liver disease ...

Using the latest data and perspectives, an international expert panel releases updated recommendations for optimal insulin ...

A new study analyzed how often people develop severe side effects after taking semaglutide — known by brand names Ozempic and ...

Novo Nordisk's collaboration with telehealth providers offers semaglutide at $499/month, enhancing access for self-paying ...

Wegovy to become preferred GLP-1 drug on CVS Caremark's top formularies in 2025 as Novo Nordisk expands patient access ...

Eli Lilly misses first-quarter estimates for earnings but beats the same for sales. Mounjaro and Zepbound sales beat ...

The World Health Organisation plans to officially back the use of weight-loss drugs to treat obesity in adults for the first ...

Effective July 1, 2025, CVS Caremark will place Wegovy injection 2.4 mg as preferred on its commercial template formularies.